Treatment of Refractory Mastocytic Enterocolitis with Budesonide

Merin Elizabeth Kuruvilla¹, Sonia Mathew², Vaidehi Avadhani³

INTRODUCTION

Mast cells (MCs) are being increasingly implicated as a possible contributor to symptoms in diarrhea predominant irritable bowel syndrome (IBS). The term “mastocytic enterocolitis” was proposed by Jakate et al. [1] to describe an increase in mucosal MCs in patients with chronic diarrhea due to functional gastrointestinal disease (FGID). The efficacy of anti–MC mediator therapy (antihistamines and MC stabilizers) has been well documented in this setting. Here we describe the treatment with oral budesonide of mastocytic enterocolitis refractory to standard anti-MC therapy.

CASE REPORT

Our patient is a 39-year-old man who suffered from chronic constipation alternating with diarrhea for several years, suggestive of IBS. He had no other cutaneous signs or systemic symptoms. Five months prior to presentation, symptoms acutely worsened, with intermittent sharp abdominal pain, bloating, and diarrhea occurring up to eight times per day. There were no identifiable food triggers, or evidence of infectious gastroenteritis. Empirical dietary eliminations had been unsuccessful at ameliorating symptoms. In addition, he had a history of allergic rhinitis, Asperger syndrome and epilepsy.

Computerized tomography with contrast showed a fatty pancreas and mildly dilated small bowel concerning for enteritis. Colonoscopy did not detect any lesions. Histology examination depicted significant associated tissue eosinophilia (Fig. 1). Mast cells tryptase immunostaining found increased MC infiltration (up to 25 per high power field, hpf) within the lamina propria (Fig. 2). Mast cells aggregates and atypical morphology such as spindle-shaped cells were not observed. CD25 co-expression was not evaluated.

Baseline tryptase and serum IgE levels were normal at 3.3 ng/ml and 66 IU/ml, respectively. Specific IgE to aeroallergens were tested due to rhinitis symptoms, and were elevated only to grass pollen. Evaluation for the c-KIT mutation was not pursued since the patient failed to meet major or other minor criteria for systemic mastocytosis and had a REMA score of 1 indicating low risk for MC clonality. The REMA score is a validated score used to predict MC clonality with a minimum threshold score of 2 [5].

The patient was diagnosed with mastocytic enterocolitis, and we initiated a regimen of cetirizine 10 mg twice daily,
and famotidine 20 mg twice daily. He reported some but not substantial improvement. The addition of oral cromolyn (200 mg prior to meals and at bedtime, up to four times daily) afforded further but incomplete relief. He continued to have episodes of abdominal cramps and diarrhea a couple of times daily. A trial of oral budesonide 3 mg three times daily was subsequently instituted, resulting in rapid and near complete resolution of abdominal pain and diarrhea output. Attempts to wean oral antihistamines were associated with mild symptom recurrence. Therefore, the patient is currently maintained on oral budesonide in conjunction with antihistamines and cromolyn sodium, and has no active symptoms.

DISCUSSION

Gastrointestinal mucosal MCs are key regulators of intestinal sensory and motor function. They have long been implicated in the pathogenesis of FGIDs, particularly in diarrhea predominant IBS [6]. Their activation and released mediators appear to contribute to the development of abdominal pain and diarrhea. A substantial increase in activated MCs releasing histamine has been observed in proximity to nerves that are correlated with abdominal pain in IBS [7]. Histamine has been shown to sensitize enteric afferents, causing visceral hypersensitivity. This has supported the role of therapeutic MC blockade with H1 and H2 blockers in FGIDs [1-4]. The MC stabilizer ketotifen was also found to significantly decrease abdominal pain and other symptoms in a prospective randomized study of IBS patients [8]. Therefore, mastocytic enterocolitis is not intended to specify a distinct diagnosis, but rather denotes potential benefit from anti-MC therapies.

Jakate et al. [1] first coined the term “mastocytic enterocolitis” to describe this excess of gastrointestinal MCs in FGIDs. It was defined as the presence of greater than 20 MCs/hpf in the gastrointestinal tract mucosa [1]. This cutoff value represented 2 standard deviations (SD) beyond the normal mean values for the colon and duodenum (13.6 and 13.2 MCs/hpf, respectively). This recommendation was used, but it is based on relatively weak evidence, and a universally accepted cutoff for significant MC counts remains unknown.

In fact, other studies have found mild or no differences in the degree of MC infiltration in IBS [9]. Based on this variability, investigators have proposed that individual MC counts in patients with diarrhea predominant FGIDs are uninterpretable. They advocate empiric MC targeted therapy in patients with unremarkable routine histology [10].

Several reports document the efficacy of H1 and H2 blockers in treatment of FGIDs with excess gastrointestinal mucosal MCs. Mast cell stabilizers also seem to have some effect in such diseases; however, the effects are rather weak and inconsistent [8]. Add-on therapy with oral budesonide was chosen since it may conceivably address mucosal inflammation associated with MC activation that leads to gastrointestinal dysfunction. The drug was well tolerated and led to almost complete symptom resolution.

Our patient did not have evidence of systemic mastocytosis (SM), which presents with gastrointestinal symptoms in 60–80% of cases, most frequently abdominal pain and diarrhea. While the major criterion for diagnosis is the presence of more than 15 MCs/hpf in an extracutaneous organ, he did not have a clinical history suggestive of SM or fulfill any of the minor criteria tested (atypical MCs and elevated serum tryptase).

CONCLUSION

This case demonstrates the potential role of budesonide, a corticosteroid with a high mucosal activity and a low bioavailability, in treating FGIDs with a possible MC component. This therapy is worth further investigation for its utility in diarrhea-predominant IBS with or without counting gastrointestinal mucosal MCs.

Conflicts of interest: None to declare.

Authors’ contributions: M.K. drafted the manuscript; S.M. reviewed the literature; V.A. pathology images and description.

REFERENCES


